Targeting the Ubiquitin–Proteasome System Using the UBA1 Inhibitor TAK-243 is a Potential Therapeutic Strategy for Small-Cell Lung Cancer
暂无分享,去创建一个
M. Tsao | A. Schimmer | R. Bremner | J. Pearson | J. Weiss | B. Lok | V. Sugumar | S. H. Barghout | M. Aparnathi | Geoffrey Liu | R. Barayan | Fariha Rahman | Lifang Song | S. Majeed | Kevin C. J. Nixon | V. Venkatasubramanian | K. Nixon
[1] Chang-Jiun Wu,et al. GRP78 determines glioblastoma sensitivity to UBA1 inhibition-induced UPR signaling and cell death , 2021, Cell Death & Disease.
[2] Tao Yu,et al. Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP/TEAD activity. , 2021, Cancer cell.
[3] Y. Pommier,et al. SLFN11 Inactivation Induces Proteotoxic Stress and Sensitizes Cancer Cells to Ubiquitin Activating Enzyme Inhibitor TAK-243 , 2021, Cancer Research.
[4] T. Ketela,et al. A genome-wide CRISPR/Cas9 screen in acute myeloid leukemia cells identifies regulators of TAK-243 sensitivity , 2021, JCI insight.
[5] P. Robson,et al. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. , 2021, Cancer cell.
[6] A. Schimmer,et al. E1 Enzymes as Therapeutic Targets in Cancer , 2021, Pharmacological Reviews.
[7] S. Rothbart,et al. Chromatin Regulation through Ubiquitin and Ubiquitin-like Histone Modifications. , 2020, Trends in biochemical sciences.
[8] N. Neamati,et al. UAE1 inhibition mediates the unfolded protein response, DNA damage and caspase-dependent cell death in pancreatic cancer , 2020, Translational oncology.
[9] T. Aittokallio,et al. SynergyFinder 2.0: visual analytics of multi-drug combination synergies , 2020, Nucleic Acids Res..
[10] B. Lok,et al. PARP inhibitors for small cell lung cancer and their potential for integration into current treatment approaches , 2020, Journal of thoracic disease.
[11] A. Chang,et al. Retrograde signaling mediates an adaptive survival response to endoplasmic reticulum stress in Saccharomyces cerevisiae , 2020, Journal of Cell Science.
[12] Q. Fan,et al. The ubiquitin system: orchestrating cellular signals in non-small-cell lung cancer , 2020, Cellular & Molecular Biology Letters.
[13] C. Rudin,et al. SCLC Subtypes De fi ned by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization , 2020 .
[14] Chuifeng Fan,et al. Identifying UBA2 as a proliferation and cell cycle regulator in lung cancer A549 cells , 2019, Journal of cellular biochemistry.
[15] A. Berger,et al. Pharmacologic inhibition of the ubiquitin-activating enzyme induces ER stress and apoptosis in chronic lymphocytic leukemia and ibrutinib-resistant mantle cell lymphoma cells , 2019, Leukemia & lymphoma.
[16] C. Rudin,et al. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data , 2019, Nature Reviews Cancer.
[17] M. Minden,et al. Preclinical evaluation of the selective small-molecule UBA1 inhibitor, TAK-243, in acute myeloid leukemia , 2018, Leukemia.
[18] P. Arvan,et al. Increased mitochondrial respiration promotes survival from endoplasmic reticulum stress , 2018, Cell Death & Differentiation.
[19] L. Byers,et al. Targeting DNA damage repair in small cell lung cancer and the biomarker landscape. , 2018, Translational lung cancer research.
[20] Y. Pommier,et al. SLFN11 Blocks Stressed Replication Forks Independently of ATR. , 2018, Molecular cell.
[21] S. Tirrell,et al. A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment , 2018, Nature Medicine.
[22] Jianfei Qi,et al. Ubiquitin ligases in oncogenic transformation and cancer therapy , 2017, Nature Reviews Cancer.
[23] C. Dive,et al. Targeting DNA damage in SCLC. , 2017, Lung cancer.
[24] Pooja Shah,et al. Probing the roles of SUMOylation in cancer cell biology by using a selective SAE inhibitor. , 2017, Nature chemical biology.
[25] Ann E. Sizemore,et al. Computational correction of copy-number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells , 2017, Nature Genetics.
[26] C. Rudin,et al. Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis. , 2017, Cancer cell.
[27] Feng-jun Liu,et al. Activation of endoplasmic reticulum stress promotes autophagy and apoptosis and reverses chemoresistance of human small cell lung cancer cells by inhibiting the PI3K/AKT/mTOR signaling pathway , 2016, Oncotarget.
[28] C. Rudin,et al. PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer , 2016, Clinical Cancer Research.
[29] Junjie Chen,et al. SLFN11 inhibits checkpoint maintenance and homologous recombination repair , 2016, EMBO reports.
[30] Martin Vingron,et al. Comprehensive genomic profiles of small cell lung cancer , 2015, Nature.
[31] Q. Gao,et al. Overactivated neddylation pathway as a therapeutic target in lung cancer. , 2014, Journal of the National Cancer Institute.
[32] Y. Pommier,et al. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. , 2012, Cancer research.
[33] Adam A. Margolin,et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.
[34] A. Ashworth,et al. The potential of exploiting DNA-repair defects for optimizing lung cancer treatment , 2012, Nature Reviews Clinical Oncology.
[35] Yaqin Tu,et al. The Ubiquitin Proteasome Pathway (UPP) in the regulation of cell cycle control and DNA damage repair and its implication in tumorigenesis. , 2012, International journal of clinical and experimental pathology.
[36] Neal Rosen,et al. Targeted cancer therapies , 2011, Chinese journal of cancer.
[37] James Lowe,et al. Ubiquitin-like protein conjugation and the ubiquitin–proteasome system as drug targets , 2010, Nature Reviews Drug Discovery.
[38] H. Walden,et al. Ubiquitin signalling in DNA replication and repair , 2010, Nature Reviews Molecular Cell Biology.
[39] R. Orlowski,et al. Proteasome inhibitors in the treatment of multiple myeloma , 2009, Leukemia.
[40] T. Hamilton,et al. Platinum Resistance: The Role of DNA Repair Pathways , 2008, Clinical Cancer Research.
[41] E. Gelmann,et al. The ubiquitin-proteasome pathway and its role in cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] G. Kalemkerian,et al. Small cell lung cancer , 2010, Seminars in Respiratory and Critical Care Medicine.
[43] K. Kok,et al. The ubiquitin‐activating enzyme E1‐like protein in lung cancer cell lines , 2000, International journal of cancer.
[44] C. I. Bliss. THE TOXICITY OF POISONS APPLIED JOINTLY1 , 1939 .